Actively Recruiting
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
Led by Hamilton Health Sciences Corporation · Updated on 2025-07-29
20
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
Sponsors
H
Hamilton Health Sciences Corporation
Lead Sponsor
M
McMaster University
Collaborating Sponsor
AI-Summary
What this Trial Is About
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
CONDITIONS
Official Title
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a physician diagnosis of prostate cancer
- Must be receiving or planned to receive androgen deprivation therapy (gonadotropin releasing hormone agonist or antagonist with or without androgen receptor pathway inhibitor)
- Elevated BMI: 30 kg/m2 or higher, or 27 kg/m2 or higher with at least one of hypertension, type 2 diabetes, obstructive sleep apnea, or dyslipidemia
You will not qualify if you...
- Have type 1 diabetes
- Currently taking a GLP-1 receptor agonist
- Under 18 years of age
- History of pancreatitis
- Personal or family history of medullary thyroid cancer
- Diagnosis of multiple endocrine neoplasia type 2
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V1C3
Actively Recruiting
Research Team
S
Sarah Karampatos, BASc, MSc
CONTACT
S
Steven Agapay, BSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here